scholarly journals Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? Against

2018 ◽  
Vol 14 (1) ◽  
pp. 14
Author(s):  
Robert Chandler ◽  
Antonella Petremolo ◽  
Pasquale Rescigno ◽  
Johann de Bono
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Metastatic Prostate Cancer ◽  
Elderly Population ◽  
Recurrent Disease ◽  
Early Stage ◽  
Optimal Management ◽  
Heterogenous Group ◽  
Number Of Patients ◽  
Enhanced Imaging

The advent of enhanced imaging in prostate cancer has resulted in recurrent disease being identified earlier. This has led to an increase in the number of patients undergoing intervention at this early stage. There remains, however, a paucity of level one evidence to advise on the optimal management of this heterogenous group, with a significant number of patients experiencing biochemical relapse unlikely to die of metastatic prostate cancer. More work is needed to define those who do and do not require intervention, to avoid doing harm to an often elderly population.

scholarly journals Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence

2015 ◽  
Vol 116 (4) ◽  
pp. 556-567 ◽  
Author(s):  
Mohammed Alshalalfa ◽  
Anamaria Crisan ◽  
Ismael A. Vergara ◽  
Mercedeh Ghadessi ◽  
Christine Buerki ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Biochemical Recurrence ◽  
Metastatic Prostate Cancer ◽  
Genomic Analysis ◽  
Prostate Cancer Progression

scholarly journals Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?

2021 ◽  
Author(s):  
Christina Niklas ◽  
Matthias Saar ◽  
Alessandro Nini ◽  
Johannes Linxweiler ◽  
Stefan Siemer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Biochemical Recurrence ◽  
Metastatic Prostate Cancer ◽  
Locally Advanced ◽  
Survival Rates ◽  
Term Survival ◽  
Long Term Survival ◽  
Hormonal Manipulation

Abstract Purpose A number of observational clinical studies suggest that prior primary tumor treatment favorably influences the course of metastatic prostate cancer (PCa), but its mechanisms of action are still speculative. Here, we describe the long-lasting sensitivity to various forms of androgen deprivation in patients after radical prostatectomy (RP) for locally advanced PCa as one potential mechanism. Methods A consecutive series of 115 radical prostatectomies after inductive therapy for T4 prostate cancer was re-analyzed, and long-term survival, as well as recurrence patterns and responses to different forms of hormonal manipulation, were assessed. Results The estimated biochemical response-free, PCa-specific, and overall survival rates after 200 months were 20%, 65%, and 47% with a median overall survival of 156 months. The majority of patients, although not cured of locally advanced PCa (84/115), showed long-term survival after RP. PCa-specific and overall survival rates of these 84 patients with biochemical recurrence were 61% and 44% at 150 months. Long-term sensitivity to ADT was found to be the main reason for the favorable tumor-specific survival in spite of biochemical recurrence. Conclusions Sensitivity to primary or secondary hormonal manipulation was the main reason for the long-term survival of patients who had not been cured by surgery only. The results suggest that treatment of the primary tumor-bearing prostate delays castration-resistant PCa and enhances the effect of hormonal therapies in a previously unknown manner. The underlying cellular and molecular mechanisms need to be explored in more detailed analyses, which could profoundly impact treatment concepts of locally advanced and metastatic PCa.

scholarly journals Early stage prostate cancer: biochemical recurrence after treatment

2014 ◽  
Vol 40 (2) ◽  
pp. 137-145
Author(s):  
Danielle A. Zanatta ◽  
Reginaldo J. Andrade ◽  
Eduardo F. Pacagnan ◽  
Lucas W. München ◽  
Rosangela A. B. Assumpção ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Early Stage

scholarly journals The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of prostate cancer after prostatectomy

2020 ◽  
Vol 61 (6) ◽  
pp. 908-919
Author(s):  
Hitoshi Ishikawa ◽  
Keiko Higuchi ◽  
Takuya Kaminuma ◽  
Yutaka Takezawa ◽  
Yoshitaka Saito ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Biochemical Recurrence ◽  
Survival Rates ◽  
Specific Antigen ◽  
Surgical Margin ◽  
Salvage Radiotherapy ◽  
Psa Kinetics ◽  
Prostate Bed ◽  
Number Of Patients

Abstract The feasibility and efficacy of hypofractionated salvage radiotherapy (HS-RT) for prostate cancer (PC) with biochemical recurrence (BR) after prostatectomy, and the usefulness of prostate-specific antigen (PSA) kinetics as a predictor of BR, were evaluated in 38 patients who received HS-RT without androgen deprivation therapy between May 2009 and January 2017. Their median age, PSA level and PSA doubling time (PSA-DT) at the start of HS-RT were 68 (53–74) years, 0.28 (0.20–0.79) ng/ml and 7.7 (2.3–38.5) months, respectively. A total dose of 60 Gy in 20 fractions (three times a week) was three-dimensionally delivered to the prostate bed. After a median follow-up of 62 (30–100) months, 19 (50%) patients developed a second BR after HS-RT, but only 1 patient died before the last follow-up. The 5-year overall survival and BR-free survival rates were 97.1 and 47.4%, respectively. Late grade 2 gastrointestinal and genitourinary morbidities were observed in 0 and 5 (13%) patients, respectively. The PSA level as well as pathological T-stage and surgical margin status were regarded as significant predictive factors for a second BR by multivariate analysis. BR developed within 6 months after HS-RT in 11 (85%) of 13 patients with a PSA-DT < 10 months compared with 1 (17%) of 6 with a PSA-DT ≥ 10 months (median time to BR: 3 vs 14 months, P < 0.05). Despite the small number of patients, our HS-RT protocol seems feasible, and PSA kinetics may be useful for predicting the risk of BR and determining the appropriate follow-up schedule.

PD24-11 EVALUATION OF A MULTIMODAL STRATEGY TO ACCELERATE DRUG EVALUATIONS IN EARLY STAGE METASTATIC PROSTATE CANCER

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Matthew O'Shaughnessy ◽  
Sean McBride ◽  
Hebert Alberto Vargas ◽  
Karim Touijer ◽  
Michael Morris ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Early Stage ◽  
Multimodal Strategy

scholarly journals Identification a potential therapeutic target in castrate resistance prostate cancer by using microarray

2018 ◽  
Vol 9 (SPL1) ◽  
Author(s):  
Massar Ibrahim Shekhan
Keyword(s):  
Prostate Cancer ◽  
Cell Line ◽  
Lncap Cell ◽  
Early Stage ◽  
Cancer Cell Line ◽  
Mrna Levels ◽  
Line Model ◽  
Cell Line Model ◽  
Number Of Patients ◽  
Significant Difference

The androgen receptor (AR) has a crucial role in the proliferation and progression of prostate cancer. anti-androgen therapy is used in the early stage of the disease and the patients respond well,howevera significant number of patients eventually will develop resistance,entering a castrate-resistant state,with very poor prognosis,which is a major clinical challenge at the moment. Enzalutamide,have shown potential in the treatment of CRPC patients,but response is just 50% and the development of resistance to these are challenging clinic. This study aims to investigate the whole genomic expression of LNCaP prostate cancer cell line model,compared to resistant to Enzalutamide model. TROP-2 demonstrates high expression in Enzalutamide resistant cells in our gene microarray,which mightsuggest TROP-2 may serve as a biomarker of resistance. The preliminary data reveal an increase in expression of TROP-2 in the LNCaP-Enz-R cell line model,compared with parental LNCaP cell,at both the protein and mRNA levels. siRNA againstTROP-2 led a decreases in a proliferation and cell cycle progression of the LNCaP-Enz-R cell line,whereas no significant difference was noticed in the parental,androgen sensitive LNCaP cell line. In addition,Knockdown of TROP-2 decrease migration of LNCaP-Enz-R cell line significantly,while no effect was observed in parental LNCaP cell

scholarly journals Modification of biochemical recurrence risk in patients with localized prostate cancer after radical prostatectomy with combined histomorphological changes in the peritumoral zone

2018 ◽  
Vol 99 (3) ◽  
pp. 408-415
Author(s):  
F S Bova ◽  
O I Kit ◽  
A Yu Maksimov ◽  
N S Karnaukhov
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Chronic Inflammation ◽  
Biochemical Recurrence ◽  
Intraepithelial Neoplasia ◽  
Prostatic Intraepithelial Neoplasia ◽  
Localized Prostate Cancer ◽  
Risk Of Recurrence ◽  
Number Of Patients ◽  
Risk Of Cancer

Aim. To assess the prognostic significance of histopathological processes in the peritumoral zone with respect to the risk of biochemical recurrence in patients with localized prostate cancer after radical prostatectomy. Methods. Histomorphological studies were conducted in the perifocal area of surgical tissue samples from 309 patients with localized prostate cancer (T1c-2cN0M0) after a radical surgery using light microscopy. Four groups of patients were identified depending on the risk of recurrence. Enzyme immunoassay was used to determine the concentration of prostate-specific antigen in the serum at baseline and every 3 months for two years after the surgery to detect biochemical recurrence. Results. Histomorphological examination of the peritumoral zone made it possible to identify histopathological processes associated with adenocarcinoma in 257 out of 309 (83.2%) patients with localized prostate cancer. The risk of biochemical recurrence of a combination of prostatic adenocarcinoma and prostatic intraepithelial neoplasia-2 increased by 3.3 (p=0.02), and of a combination of adenocarcinoma, neoplasia and chronic inflammation in the perifocal zone increased by 4.5 times (p=0.005) compared to patients without histopathological changes of the peritumoral zone. In combination of prostate adenocarcinoma with neoplasia and chronic inflammation in the peritumoral zone, the number of patients with an intermediate risk of cancer recurrence after surgical treatment increased due to decrease of the proportion of patients with very low and low risk of recurrence of the oncologic disease. Conclusion. The combination of prostate cancer with high-grade prostatic intraepithelial neoplasia and chronic inflammation in the peritumoral zone modifies the risk of biochemical recurrence of cancer after radical prostatectomy.

Ascertainment of Veterans With Metastatic Prostate Cancer in Electronic Health Records: Demonstrating the Case for Natural Language Processing

2021 ◽  
pp. 1005-1014
Author(s):  
Patrick R. Alba ◽  
Anthony Gao ◽  
Kyung Min Lee ◽  
Tori Anglin-Foote ◽  
Brian Robison ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Natural Language Processing ◽  
Natural Language ◽  
Language Processing ◽  
Metastatic Prostate Cancer ◽  
Cancer Registries ◽  
Veterans Affairs ◽  
Department Of Veterans Affairs ◽  
Cancer Registry Data ◽  
Number Of Patients

PURPOSE Prostate cancer (PCa) is among the leading causes of cancer deaths. While localized PCa has a 5-year survival rate approaching 100%, this rate drops to 31% for metastatic prostate cancer (mPCa). Thus, timely identification of mPCa is a crucial step toward measuring and improving access to innovations that reduce PCa mortality. Yet, methods to identify patients diagnosed with mPCa remain elusive. Cancer registries provide detailed data at diagnosis but are not updated throughout treatment. This study reports on the development and validation of a natural language processing (NLP) algorithm deployed on oncology, urology, and radiology clinical notes to identify patients with a diagnosis or history of mPCa in the Department of Veterans Affairs. PATIENTS AND METHODS Using a broad set of diagnosis and histology codes, the Veterans Affairs Corporate Data Warehouse was queried to identify all Veterans with PCa. An NLP algorithm was developed to identify patients with any history or progression of mPCa. The NLP algorithm was prototyped and developed iteratively using patient notes, grouped into development, training, and validation subsets. RESULTS A total of 1,144,610 Veterans were diagnosed with PCa between January 2000 and October 2020, among which 76,082 (6.6%) were identified by NLP as having mPCa at some point during their care. The NLP system performed with a specificity of 0.979 and sensitivity of 0.919. CONCLUSION Clinical documentation of mPCa is highly reliable. NLP can be leveraged to improve PCa data. When compared to other methods, NLP identified a significantly greater number of patients. NLP can be used to augment cancer registry data, facilitate research inquiries, and identify patients who may benefit from innovations in mPCa treatment.

Sign in / Sign up

Export Citation Format

Share Document